Jpmorgan Chase & CO Renalytix PLC Transaction History

Jpmorgan Chase & CO

$1.22 Trillion
Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Renalytix PLC stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1 shares of RNLX stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 16,165 99.99%

Holding current value

Previous $3,000 100.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	SELL	$0.21 - $0.45 $3,394 - $7,273	-16,164 Reduced 99.99%	1 $0
Q2 2024 Aug 12, 2024	SELL	$0.23 - $0.93 $5,941 - $24,022	-25,831 Reduced 61.51%	16,165 $3,000
Q1 2024 May 10, 2024	SELL	$0.26 - $1.47 $1,646 - $9,309	-6,333 Reduced 13.1%	41,996 $36,000
Q4 2023 Feb 12, 2024	SELL	$0.33 - $1.61 $7,147 - $34,872	-21,660 Reduced 30.95%	48,329 $18,000
Q3 2023 Nov 14, 2023	SELL	$1.51 - $4.01 $7,752 - $20,587	-5,134 Reduced 6.83%	69,989 $111,000
Q2 2023 Aug 11, 2023	SELL	$2.0 - $2.92 $11,580 - $16,906	-5,790 Reduced 7.16%	75,123 $219,000
Q1 2023 May 11, 2023	SELL	$1.93 - $3.72 $2,422 - $4,668	-1,255 Reduced 1.53%	80,913 $195,000
Q4 2022 Feb 13, 2023	SELL	$1.06 - $2.21 $4,139 - $8,630	-3,905 Reduced 4.54%	82,168 $153,000
Q3 2022 Nov 14, 2022	SELL	$1.19 - $2.78 $2,781 - $6,496	-2,337 Reduced 2.64%	86,073 $110,000
Q2 2022 Aug 11, 2022	BUY	$2.45 - $7.81 $107,123 - $341,484	43,724 Added 97.85%	88,410 $218,000
Q1 2022 May 11, 2022	BUY	$5.88 - $15.9 $81,038 - $219,133	13,782 Added 44.6%	44,686 $309,000
Q4 2021 Feb 10, 2022	BUY	$13.43 - $27.4 $332,258 - $677,876	24,740 Added 401.36%	30,904 $492,000
Q3 2021 Nov 12, 2021	BUY	$17.91 - $34.78 $110,397 - $214,383	6,164 New	6,164 $124,000

Others Institutions Holding RNLX

# of Institutions

Shares Held

3.91M

Call Options Held

13.7K

Put Options Held

View Full List

About Renalytix plc

Ticker RNLX
Exchange OTC
Sector Healthcare
Industry Health Information Services
Shares Outstandng 37,445,900
Market Cap $5.62M
Description
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data ...

More about RNLX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Renalytix PLC Transaction History